



Dr. med. Daniel Weilenmann

chief of service
Kardiologie · Dept. I

Contact

Dr. med. Daniel Weilenmann
Rorschacherstrasse 95
9007 St. Gallen
Switzerland

T +41 71 494 1051
daniel.weilenmann@kssg.ch

Units

Kardiologie

Profile Function

chief of service

Publications (73)

Breuss A, Porsch M, Aschmann A, Weber L, Appert S, Haager P, Weilenmann D, Wildermuth S, Rickli H, Maeder M. Pleural effusion in severe aortic stenosis: marker of an adverse haemodynamic constellation and poor prognosis. *ESC Heart Fail* 2024

Brenner R, Drescher T, Locher R, Bilz S, Rickli H, Brändle M, Nobel D, Weilenmann D, Ammann P, Maeder M. Pulmonary and Systemic Hemodynamics in Patients with Hyperthyroidism. *Am J Med* 2023

Breuss A, Aschmann A, Porsch M, Weber L, Appert S, Haager P, Weilenmann D, Wildermuth S, Rickli H, Maeder M. Pulmonary Congestion by Conventional Chest Radiography: Relationship With Hemodynamics and Mortality in Patients With Severe Aortic Stenosis. *CJC Open* 2023; 5:938-946.

Rubini Gimenez M, Scheller B, Farah A, Ohlow M, Mangner N, Weilenmann D, Wöhrle J, Cuculi F, Leibundgut G, Möbius-Winkler S, Cattaneo M, Gilgen N, Kaiser C, Jeger R. Sex-specific inequalities in the use of drug-coated balloons for small coronary artery disease: a report from the BASKET-SMALL 2 trial. *Clin Res Cardiol* 2023

Otto S, Díaz V, Weilenmann D, Cuculi F, Nuruddin A, Leibundgut G, Alfonso F, Wan Ahmad W, Pyxaras S, Rittger H, Steen P, Gaede L, Schulze C, Wöhrle J, Rosenberg M, Waliszewski M. Crystalline sirolimus-coated balloon (cSCB) angioplasty in an all-comers, patient population with stable and unstable coronary artery disease including chronic total occlusions: rationale, methodology and design of the SCORE trial. *BMC Cardiovasc Disord* 2023; 23:176.

Seeger J, Wöhrle J, Scheller B, Farah A, Ohlow M, Mangner N, Möbius-Winkler S, Weilenmann D, Stachel G, Leibundgut G, Rickenbacher P, Cattaneo M, Gilgen N, Kaiser C, Jeger R, On Behalf Of The Basket-Small Investigators. Impact of Insulin-Treated Compared to Non-Insulin-Treated Diabetes Mellitus on Outcome of Percutaneous Coronary Intervention with Drug-Coated Balloons versus Drug-Eluting Stents in De Novo Coronary Artery Disease: The Randomized BASKET-SMALL 2 Trial. *J Cardiovasc Dev Dis* 2023; 10

Avran A, Zuffi A, Gobbi C, Gasperetti A, Schiavone M, Werner G, Kambis M, Boudou N, Galassi A, Sianos G, Idali M, Garbo R, Gagnor A, Gasparini G, Bufe A, Bryniarski L, Kalnins A, Weilenmann D, Wojcik J, Agostoni P, Bozinovic N, Carlino M, Furkalo S, Hildick-Smith D, Drogoul L, Lemoine J, Serra A, Carugo S, Ungi I, Dens J, Reifart N, Cosma J, Mallia V, Vadalà G, Biondi-Zoccai G, di Mario C. Gender differences in percutaneous coronary intervention for chronic total occlusions from the ERCTO study. *Catheter Cardiovasc Interv* 2023; 101:918-931.

Appert S, Weber L, Breuss A, Haager P, Joerg L, Weilenmann D, Chronis J, Rigger J, Rickli H, Maeder M. Estimated glomerular filtration rate, haemodynamics, and mortality in patients with aortic stenosis. *Eur J Clin Invest* 2023:e13965.

Wagener M, Boeddinghaus J, Gaemperli O, Räber L, Nietlispach F, Meier P, Muller O, Weilenmann D, Jeger R. Trends in Coronary and Structural Heart Interventions in Switzerland over the Last 16 Years and Impact of COVID-19: Insights from the National Swiss PCI Survey. *J Clin Med* 2022; 11

Maeder M, Rickli H, Weber L, Weilenmann D, Ammann P, Joerg L, Haager P, Rigger J, Chronis J, Brenner R. Systemic blood pressure in severe aortic stenosis: Haemodynamic correlates and long-term prognostic impact. *ESC Heart Fail* 2022; 10:274-283.

Scheller B, Rissanen T, Farah A, Ohlow M, Mangner N, Wöhrle J, Möbius-Winkler S, Weilenmann D, Leibundgut G, Cuculi F, Gilgen N, Coslovsky M, Mahfoud F, Jeger R, BASKET-SMALL 2 Investigators. Drug-Coated Balloon for Small Coronary Artery Disease in Patients With and Without High-Bleeding Risk in the BASKET-SMALL 2 Trial. *Circ Cardiovasc Interv* 2022; 15:e011569.

Maufoud F, Farah A, Ohlow M, Mangner N, Wöhrle J, Möbius-Winkler S, Weilenmann D, Leibundgut G, Cuculi F, Gilgen N, Kaiser C, Cattaneo M, Scheller B, Jeger R. Drug-coated balloons for small coronary artery disease in patients with chronic kidney disease: a pre-specified analysis of the BASKET-SMALL 2 trial. *Clin Res Cardiol* 2022; 111:806-815.

Mangner N, Farah A, Ohlow M, Möbius-Winkler S, Weilenmann D, Wöhrle J, Linke A, Stachel G, Markovic S, Leibundgut G, Rickenbacher P, Cattaneo M, Gilgen N, Kaiser C, Scheller B, Jeger R, BASKET-SMALL 2 Investigators. Safety and Efficacy of Drug-Coated Balloons Versus Drug-Eluting Stents in Acute Coronary Syndromes: A Prespecified Analysis of BASKET-SMALL 2. *Circ Cardiovasc Interv* 2022; 15:e011325.

Seidl S, Rigger J, Chronis J, Rohner F, Jörg L, Haager P, Ammann P, Weilenmann D, Rogowski S, Rickli H, Maeder M. Long-term follow-up of medically treated patients with spontaneous coronary artery dissection: a prospective, Swiss single-centre cohort study. *Swiss Med Wkly* 2021; 151:w30067.

Weber L, Ehl N, Buser M, Rigger J, Chronis J, Weilenmann D, Jörg L, Haager P, Rickli H, Maeder M. Hemodynamics Prior to Valve Replacement for Severe Aortic Stenosis and Pulmonary Hypertension during Long-Term Follow-Up. *J Clin Med* 2021; 10

Maeder M, Haager P, Rigger J, Chronis J, Joerg L, Hochholzer D, Weilenmann D, Seidl S, Weber L, Rickli H. Wedge Pressure vs Left Ventricular End-Diastolic Pressure for Pulmonary Hypertension Classification and Prognostication in Severe Aortic Stenosis. *CJC Open* 2021; 3:1428-1437.

Maeder M, Schoch O, Neumann T, Brutsche M, Haager P, Pohle S, Joerg L, Chronis J, Weilenmann D, Weber L, Rickli H. Impact of the new pulmonary hypertension definition on long-term mortality in patients with severe aortic stenosis undergoing valve replacement. *Clin Cardiol* 2021; 44:1276-1285.

Wagener M, Jeger R, Weilenmann D, Räber L, Nietlispach F, Muller O, Meier P, Gämperli O, Cook S, Twerenbold R, On Behalf Of The Swiss Working Group Interventional Cardiology Of The Swiss Society Of Cardiology. Coronary and structural heart interventions in Switzerland 2019. *Swiss Med Wkly* 2021; 151:w20495.

Iglesias J, Windecker S, Valgimigli M, Heg D, Kaiser C, Weilenmann D, Kurz D, Roffi M, Losdat S, Muller O, Pilgrim T. Multivessel percutaneous coronary intervention with thin-strut biodegradable versus durable polymer drug-eluting stents in ST-segment elevation myocardial infarction: A subgroup analysis of the BIOSTEMI randomized trial. *Int J Cardiol* 2021; 334:37-41.

Iglesias J, Windecker S, Jüni P, Valgimigli M, Cuculi F, Kaiser C, Weilenmann D, Cook S, Brinkert M, Muller O, Tüller D, Degrauwe S, Roffi M, Heg D, Pilgrim T. Five-Year Outcomes With Biodegradable-Polymer Sirolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents in Patients With Acute Coronary Syndrome: A Subgroup Analysis of the BIOSCIENCE Trial. *Cardiovasc Revasc Med* 2021; 34:3-10.

Wöhrle J, Jeger R, Kaiser C, Gilgen N, Cattaneo M, Rickenbacher P, Leibundgut G, Stachel G, Weilenmann D, Möbius-Winkler S, Mangner N, Ohlow M, Farah A, Seeger J, Scheller B, BASKET-SMALL 2 Investigators. Impact of Diabetes on Outcome With Drug-Coated Balloons Versus Drug-Eluting Stents: The BASKET-SMALL 2 Trial. *JACC Cardiovasc Interv* 2021; 14:1789-1798.

Maeder M, Rigger J, Chronis J, Ammann P, Rohner F, Jörg L, Haager P, Weilenmann D, Weber L, Rickli H. Impact of a volume challenge on haemodynamics and prognosis in patients with severe aortic stenosis. *ESC Heart Fail* 2020

Jeger R, Scheller B, Kaiser C, Gilgen N, Cattaneo M, Osswald S, Rickenbacher P, Leibundgut G, Markovic S, Stachel G, Wöhrle J, Weilenmann D, Möbius-Winkler S, Mangner N, Ohlow M, Farah A, BASKET-SMALL 2 Investigators. Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial. *Lancet* 2020; 396:1504-1510.

Maeder M, Maisano F, Ehl N, Buser M, Taramasso M, Jörg L, Haager P, Weilenmann D, Weber L, Rickli H. Invasive Hemodynamic Staging Classification of Cardiac Damage in Patients With Aortic Stenosis Undergoing Valve Replacement. *Can J Cardiol* 2020

Iglesias J, Windecker S, Jüni P, Valgimigli M, Cuculi F, Kaiser C, Weilenmann D, Cook S, Moarof I, Muller O, Rigamonti F, Lanz J, Tüller D, Roffi M, Heg D, Pilgrim T. Five-Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents. *J Am Heart Assoc* 2019; 8:e013607.

Schiefer R, Rickli H, Neurauter E, Buser M, Weilenmann D, Maeder M. Non-invasive assessment prior to invasive coronary angiography in routine clinical practice in Switzerland - Is it according to the guidelines?. *PLoS one* 2019; 14:e0222137.

Iglesias J, Windecker S, Jüni P, Zwahlen M, Odutayo A, Valgimigli M, Eeckhout E, Losdat S, Stortecky S, Tapponnier M, Kaiser C, Weilenmann D, Moarof I, Kurz D, Roffi M, Heg D, Muller O, Pilgrim T. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial. *Lancet* 2019; 394:1243-1253.

Iglesias J, Windecker S, Jüni P, Häner J, Cuculi F, Kaiser C, Weilenmann D, Cook S, Moarof I, Muller O, Noble S, Tüller D, Roffi M, Heg D, Pilgrim T. Long-Term Effect of Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents in Patients With Small Vessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the BIOSCIENCE Randomized Trial. *Circ Cardiovasc Interv* 2019; 12:e008024.

Jeger R, Weilenmann D, Rickli H, Hansen K, Rickenbacher P, Conen D, Müller C, Osswald S, Gilgen N, Vuilliomenet A, Pedrazzini G, Pfisterer M, Vogt D, Galatius S, Abildgaard U, Naber C, Alber H, Eberli F, Kurz D, Kaiser C. Competing risks of major bleeding and thrombotic events with prasugrel-based dual antiplatelet therapy after stent implantation - An observational analysis from BASKET-PROVE II. *PLoS one* 2019; 14:e0210821.

Weber L, Maisano F, Baier P, Taramasso M, Brenner R, Weilenmann D, Jörg L, Haager P, Rickli H, Maeder M. Haemodynamic mechanisms and long-term prognostic impact of pulmonary hypertension in patients with severe aortic stenosis undergoing valve replacement. *Eur J Heart Fail* 2018

Jeger R, Stephan F, Mueller C, Rickenbacher P, Coslovsky M, Gilgen N, Osswald S, Kaiser C, Scheller B, Linke A, Mahfoud F, Schreiber M, Farah A, Ohlow M, Mangner N, Möbius-Winkler S, Leibundgut G, Weilenmann D, Wöhrle J, Richter S, BASKET-SMALL 2 Investigators. Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial. *Lancet* 2018; 392:849-856.

Pilgrim T, Jüni P, Eberli F, Hunziker L, Cuculi F, Kaiser C, Weilenmann D, Cook S, Siontis G, Moarof I, Muller O, Tüller D, Roffi M, Heg D, Piccolo R, Windecker S. Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial. *Lancet* 2018; 392:737-746.

Iglesias J, Windecker S, Jüni P, Eeckhout E, Valgimigli M, Heg D, Tapponnier M, Kaiser C, Weilenmann D, Vuilliomenet A, Kurz D, Roffi M, Zaugg S, Muller O, Pilgrim T. A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the BIOSTEMI trial. *EuroIntervention* 2018; 14:692-699.

Gilgen N, Butter C, Bruch L, Kaiser C, Hoffmann A, Rickenbacher P, Mueller C, Stephan F, Coslovsky M, Jeger R, Krackhardt F, Zweiker R, Farah A, Scheller B, Ohlow M, Mangner N, Weilenmann D, Wöhrle J, Jamshidi P, Leibundgut G, Möbius-Winkler S, BASKET-SMALL 2 Investigators. Drug-coated balloons for de novo lesions in small coronary arteries: rationale and design of BASKET-SMALL 2. *Clin Cardiol* 2018; 41:569-575.

Schilling C, Weilenmann D, Diener S, Hundsberger T. [A Rare Cause for Transient Aphasia after Coronary Angiography]. *Praxis (Bern 1994)* 2018; 107:531-534.

Maeder M, Nägele R, Rohner P, Weilenmann D. Pulmonary hypertension in stiff left atrial syndrome: pathogenesis and treatment in one. *ESC Heart Fail* 2017

Rigamonti F, Kaiser C, Rickli H, Corti R, Röthlisberger C, Wenaweser P, Weilenmann D, Cook S, Maeder M, Fahrni G, Roffi M. Switzerland: coronary and structural heart interventions from 2010 to 2015. *EuroIntervention* 2017; 13:Z75-Z79.

Maeder M, Schoch O, Kleiner R, Joerg L, Weilenmann D, Swiss Society For Pulmonary Hypertension. Pulmonary hypertension associated with left-sided heart disease. *Swiss Med Wkly* 2017; 147:w14395.

Rogowski S, Maeder M, Weilenmann D, Haager P, Ammann P, Rohner F, Jörg L, Rickli H. Spontaneous Coronary Artery Dissection: Angiographic Follow-Up and Long-Term Clinical Outcome in a Predominantly Medically Treated Population. *Catheter Cardiovasc Interv* 2015

Pilgrim T, Jüni P, Wenaweser P, Blöchliger S, Nietlispach F, Rigamonti F, Taniwaki M, Khattab A, Jamshidi P, Kaiser C, Weilenmann D, Cook S, Muller O, Vuilliomenet A, Tüller D, Roffi M, Heg D, Piccolo R, Windecker S. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction. *EuroIntervention* 2015; 11

Maeder M, Kleiner R, Weilenmann D. Severely worsening dyspnea after initiation of macitentan therapy for pulmonary arterial hypertension. *Int J Cardiol* 2015; 202:244-5.

Häfliger M, Weilenmann D, Rickli H, Maeder M. Recurrent left anterior descending artery spasm causing transmural ischaemia treated with stenting. *Eur Heart J* 2015

Franzone A, Jüni P, Wenaweser P, Stortecky S, Räber L, Jamshidi P, Kaiser C, Weilenmann D, Cook S, Muller O, Vuilliomenet A, Tüller D, Roffi M, Heg D, Pilgrim T, Windecker S. Clinical outcomes according to diabetic status in patients treated with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents: prespecified subgroup analysis of the BIOSCIENCE trial. *Circ Cardiovasc Interv* 2015; 8

Mueller-Mottet S, Nicod L, Aubert J, Popov V, Speich R, Keusch S, Hasler E, Huber L, Grendelmeier P, Tamm M, Beghetti M, Lador F, Stricker H, Domenighetti G, Azzola A, Geiser T, Schwerzmann M, Weilenmann D, Schoch O, Fellrath J, Rochat T, Ulrich S. Long-term data from the swiss pulmonary hypertension registry. *Respiration* 2015; 89:127-40.

Kaiser C, Vuillomenet A, Steiner M, von Felten S, Vogt D, Wadt Hansen K, Rickenbacher P, Conen D, Müller C, Buser P, Hoffmann A, Pfisterer M, Weilenmann D, Rickli H, Galatius S, Jeger R, Gilgen N, Skov Jensen J, Naber C, Alber H, Wanitschek M, Eberli F, Kurz D, Pedrazzini G, Moccetti T, BASKET-PROVE II study group. Long-term efficacy and safety of biodegradable-polymer sirolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial. *Circulation* 2014; 131:74-81.

Pilgrim T, Jüni P, Wenaweser P, Eberli F, Noble S, Moschovitis A, Fahrni T, Jamshidi P, Kaiser C, Weilenmann D, Cook S, Vuilliomenet A, Muller O, Tüller D, Roffi M, Heg D, Windecker S. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial. *Lancet* 2014; 384:2111-22.

Pilgrim T, Jüni P, Heg D, Jamshidi P, Kaiser C, Weilenmann D, Cook S, Vuillomenet A, Muller O, Tüller D, Roffi M, Windecker S. Randomized comparison of biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for percutaneous coronary revascularization: rationale and design of the BIOSCIENCE trial. *Am Heart J* 2014; 168:256-61.

Vollenbroich R, Maeder M, Weilenmann D. Congestive heart failure related to antifungal therapy with itraconazole. *Int J Cardiol* 2013; 172:e170-1.

Brenner R, Weilenmann D, Maeder M, Jörg L, Bluzaitte I, Rickli H, De Pasquale G, Ammann P. Clinical characteristics, sex hormones, and long-term follow-up in Swiss postmenopausal women presenting with Takotsubo cardiomyopathy. *Clin Cardiol* 2012; 35:340-7.

Maeder M, Brunner-La Rocca H, Estlinbaum W, Kiencke S, Dieterle T, Weilenmann D, Hack D, Fehr T, Ammann P, Muzzarelli S, Pfisterer M, Rickli H, TIME-CHF Investigators. Incidence, clinical predictors, and prognostic impact of worsening renal function in elderly patients with chronic heart failure on intensive medical therapy. *Am Heart J* 2012; 163:407-14, 414.e1.

Hauptle R, Weilenmann D, Schneider T, Haile S, Ammann P, Knellwolf C, Borovicka J. Individualised PPI prescription in patients on combination antiplatelet therapy and upper gastrointestinal events after percutaneous coronary intervention: a cohort study. *Wien Med Wochenschr* 2012; 162:67-73.

Ehl N, Rickli H, Jörg L, Falk V, Weilenmann D, Epp C, Thies S, Geyer R, Sündermann S, Maeder M. Constrictive pericarditis presenting as a large mediastinal mass causing functional tricuspid and pulmonary stenosis. *Circulation* 2011; 124:e487-91.

Tapernoux D, Weilenmann D, Diethelm M. Myokardinfarkt bei Suizidversuch. *Deutsche medizinische Wochenschrift (1946)* 2009; 134:339-342.

Tapernoux D, Weilenmann D, Diethelm M. Die Achillesferse der COPD-Behandlung - Myocardial infarction during attempted suicide. *Deutsche medizinische Wochenschrift (1946)* 2009; 134:339-42.

Maeder M, Amsler B, Zellweger M, Nietlispach F, Weilenmann D, Roth J, Roser H, Buser P, Pfisterer M, Kaiser C. Long-term outcomes after intracoronary Beta-irradiation for in-stent restenosis in bare-metal stents. *The Journal of invasive cardiology* 2008; 20:179-84.

Maeder M, Wolber T, Rickli H, Myers J, Hack D, Riesen W, Weilenmann D, Ammann P. B-type natriuretic peptide kinetics and cardiopulmonary exercise testing in heart failure. *International journal of cardiology* 2007; 120:391-8.

Wolber T, Maeder M, Weilenmann D, Duru F, Bluzaitte I, Riesen W, Rickli H, Ammann P. Integration of B-type natriuretic peptide levels with clinical data and exercise testing for predicting coronary artery disease. *The American journal of cardiology* 2006; 98:764-7.

Schlaudraff K, Weilenmann D, Künzli A. Images in cardiology: Rare case of pericarditis constrictiva. *Heart (British Cardiac Society)* 2005; 91:1133.

Bernheim A, Fatio R, Kiowski W, Weilenmann D, Rickli H, Brunner-La Rocca H. Atropine often results in complete atrioventricular block or sinus arrest after cardiac transplantation: an unpredictable and dose-independent phenomenon. *Transplantation* 2004; 77:1181-5.

Schalcher C, Rickli H, Brehm M, Weilenmann D, Oechslin E, Kiowski W, Brunner-La Rocca H. Prolonged oxygen uptake kinetics during low-intensity exercise are related to poor prognosis in patients with mild-to-moderate congestive heart failure. *Chest* 2003; 124:580-6.

Rickli H, Kiowski W, Brehm M, Weilenmann D, Schalcher C, Bernheim A, Oechslin E, Brunner-La Rocca H. Combining low-intensity and maximal exercise test results improves prognostic prediction in chronic heart failure. *Journal of the American College of Cardiology* 2003; 42:116-22.

Weilenmann D, Rickli H, Follath F, Kiowski W, Brunner-La Rocca H. Noninvasive evaluation of pulmonary capillary wedge pressure by BP response to the Valsalva maneuver. *Chest* 2002; 122:140-5.

Duru F, Bloch K, Weilenmann D, Candinas R. Clinical evaluation of a pacemaker algorithm that adjusts the pacing rate during sleep using activity variance. *Pacing and clinical electrophysiology : PACE* 2000; 23:1509-15.

Weilenmann D, Duru F, Schönbeck M, Schenk B, Zwicky P, Russi E, Candinas R. Influence of acute exposure to high altitude and hypoxemia on ventricular stimulation thresholds in pacemaker patients. *Pacing and clinical electrophysiology : PACE* 2000; 23:512-5.

Brunner-La Rocca H, Rickli H, Weilenmann D, Duru F, Candinas R. Importance of ventricular rate after mode switching during low intensity exercise as assessed by clinical symptoms and ventilatory gas exchange. *Pacing and clinical electrophysiology : PACE* 2000; 23:32-9.

Brunner-La Rocca H, Weilenmann D, Rickli H, Follath F, Kiowski W. Is blood pressure response to the Valsalva maneuver related to neurohormones, exercise capacity, and clinical findings in heart failure?. *Chest* 1999; 116:861-7.

Brunner-La Rocca H, Weilenmann D, Kiowski W, Maly F, Candinas R, Follath F. Within-patient comparison of effects of different dosages of enalapril on functional capacity and neurohormone levels in patients with chronic heart failure. *American heart journal* 1999; 138:654-62.

Brunner-La Rocca H, Weilenmann D, Schalcher C, Schlumpf M, Follath F, Candinas R, Kiowski W. Prognostic significance of oxygen uptake kinetics during low level exercise in patients with heart failure. *The American journal of cardiology* 1999; 84:741-4, A9.

Brunner-La Rocca H, Weilenmann D, Kiowski W, Maly F, Follath F. Plasma levels of enalaprilat in chronic therapy of heart failure: relationship to adverse events. *The Journal of pharmacology and experimental therapeutics* 1999; 289:565-71.

Brunner-La Rocca H, Weilenmann D, Follath F, Schlumpf M, Rickli H, Schalcher C, Maly F, Candinas R, Kiowski W. Oxygen uptake kinetics during low level exercise in patients with heart failure: relation to neurohormones, peak oxygen consumption, and clinical findings. *Heart (British Cardiac Society)* 1999; 81:121-7.

Park E, Weilenmann D, Bloch K, Kueffner J, Bornzin G, Candinas R, Levine P. Activity-controlled circadian base rate. *Pacing and clinical electrophysiology : PACE* 1998; 21:2182-6.

Brunner-La Rocca H, Weilenmann D, Bracht C, Carli S, Schlumpf M, Follath F, Kiowski W. Relative frequency of functional sympathetic and parasympathetic reinnervation after heart transplantation. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation* 1998; 17:725-8.

Brunner-La Rocca H, Kiowski W, Bracht C, Weilenmann D, Follath F. Atrioventricular block after administration of atropine in patients following cardiac transplantation. *Transplantation* 1997; 63:1838-9.

Projects (25)

SeQuent® SCB "All Comers" Post Market Clinical Follow-up (PMCF)

Clinical Studies - Oct 21, 2021 - Dec 31, 2025

Ongoing

ALFA ROMEO

Clinical Studies - Jun 23, 2021 - Jun 23, 2025

Ongoing

Cruz HBR

Clinical Studies - Jul 13, 2020 - Dec 31, 2022

Completed

iModern

Clinical Studies - Jan 20, 2019 - Dec 31, 2024

Ongoing

LEADERS FREE III

Clinical Studies - Aug 1, 2017 - Dec 31, 2021

Completed

WIN: Worldwide registry to assess the STENTYS XPOSITION S for revascularization of coronary arteries in routine clinical practice

Clinical Studies - Jan 27, 2017 - Jan 31, 2020

Completed

BIOSTEMI und BIOSTEMI Ext

Clinical Studies - Oct 12, 2016 - Dec 30, 2023

Completed

TRUNC - Multicenter prospective study of the STENTYS Xposition S for treatment of unprotected Left Main Coronary Artery Disease

Clinical Studies - May 2, 2016 - Dec 31, 2019

Completed

COBRA REDUCE - Cobra PzF Stenting to Reduce the Duration of Triple Therapy in Patients Treated with Oral Anticoagulation Undergoing Percutaneous Coronary Intervention

Clinical Studies - Jan 1, 2016 - Mar 31, 2019

Completed

SENIOR

Clinical Studies - Mar 26, 2015 - Nov 30, 2018

Completed

AMG 145 20120153 GLAGOV

Clinical Studies - Jan 9, 2014 - Jan 9, 2018

Completed

Absorb first registry

Clinical Studies - Jul 10, 2013 - Oct 1, 2015

Completed

COBRA PzF Coronary Stent System in Native Coronary Arteries for Early Healing, Thrombus Inhibition, Endothelialization, and Avoiding Long-Term Dual Anti-Platelet Therapy – The PzF SHIELD Trial

Clinical Studies - Mar 22, 2013 - Mar 31, 2021

Completed

CENTURY II

Clinical Studies - Jul 2, 2012 - Jul 2, 2016

Completed

ORSIRO

Clinical Studies - May 29, 2012 - May 29, 2016

Completed

STENTYS Sizing Registry

Clinical Studies - May 7, 2012 - Oct 31, 2019

Aborted

OPEN II

Clinical Studies - Apr 24, 2012 - Dec 31, 2018

Completed

Basket Small 2

Clinical Studies - Mar 21, 2012 - Mar 21, 2016

Completed

APPOSITION III

Clinical Studies - Feb 1, 2011 - Jan 31, 2014

Completed

DELUX Registry

Clinical Studies - Jul 14, 2010 - Jul 12, 2013

Completed

BASKET-PROVe II: Basel Stent Kosten Effektivitäts Trial-Prospektive Validation Examination, Teil II

Clinical Studies - Jun 1, 2010 - Jun 1, 2013

Completed

INPUTon PE: Multizentrische, observationelle Überwachungsstudie zur Erkennung von chronisch thromboembolischem Lungenhochdruck nach einer Lungenembolie (PE)

Clinical Studies - Mar 1, 2010 - Mar 3, 2015

Completed

SeQuent Please Registry

Clinical Studies - Jan 5, 2010 - May 1, 2012

Completed

e-Biomatrix PMR Registry: Registerstudie zur Nachmarktkontrolle des für eine Stentangioplastie verwendeten Biolimus-beschichteten Stent

Clinical Studies - Feb 3, 2009 - Jan 6, 2014

Completed

CTO-R: Treatment of coronary chronic total occlusions (CTO) by percutaneous angioplasty (PCI): A single center registry

Clinical Studies - Jan 1, 2009 - Jan 1, 2013

Automatically Closed